Search

Your search keyword '"Moldovianu, Ana-Maria"' showing total 6 results
Start Over Author "Moldovianu, Ana-Maria"
6 results on '"Moldovianu, Ana-Maria"'

1. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

Author

Moldovianu, Ana-Maria, primary, Stoia, Razvan, additional, Vasilica, Mariana, additional, Ursuleac, Iulia, additional, Badelita, Sorina Nicoleta, additional, Tomescu, Andra Alina, additional, Preda, Oana Diana, additional, Bardas, Alexandru, additional, Cirstea, Mihaela, additional, and Coriu, Daniel, additional

Published
2023
Full Text
View/download PDF

2. Kikuchi-Fujimoto disease and systemic lupus erythematosus – an enigmatic association for clinicians and pathologists: Case report and short literature review

Author

Tarabichi, Shirley, primary, Nicola, Andreea Alexandra, additional, Radu, Lucia, additional, Enache, Simona, additional, Busuioc, Constantin Ioan, additional, Moldovianu, Ana-Maria, additional, Nitu, Andra-Florina, additional, Predeteanu, Denisa, additional, and Sarafoleanu, Codrut, additional

Published
2022
Full Text
View/download PDF

6. The Difficult-to-Treat del 17 p Patient—A Case Report in Chronic Lymphocytic Leukemia.

Author

Moldovianu, Ana-Maria, Crisan, Ana Manuela, Varady, Zsofia, and Coriu, Daniel

Subjects
CHRONIC lymphocytic leukemia, STEM cell transplantation, LONG-term health care, LYMPHOCYTES, IBRUTINIB
Abstract

Chronic lymphocytic leukemia (CLL) treatment strategies have evolved to include mechanism-driven drugs but now raise new questions regarding their optimum timing and sequencing. In high-risk patients, switching from pathway inhibitors to allogeneic stem cell transplantation (allo-HCT) is still a matter of intense debate. We report the case of a CLL patient with 17 p deletion treated with ibrutinib as a bridge to allo-HCT. Early relapse after allo-HCT urged the initiation of salvage therapy, including donor lymphocytes infusions, ibrutinib, and venetoclax. We aim to outline and discuss the potential benefits of novel therapies, the current role of allo-HCT in CLL, drug timing and sequencing, and the unmet need to improve the long-term outcome of high-risk CLL patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results